Science AI Journal
Medicine · Research topic

Open research questions in Cholangiocarcinoma and Gallbladder Cancer Studies

93 unresolved questions extracted from the limitations and future-work sections of 183 Cholangiocarcinoma and Gallbladder Cancer Studies papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • The non-specific symptoms of GBC lead to rapid progression and poor prognosis. The lack of understanding of the geographic and genetic diversity in GBC mutation profiles hinders the development of targeted therapies. The study of GBC is challenging due to its aggressive nature and limited treatment options.

    Geographic and genetic diversity in gallbladder cancer mutation profiles: insights from a worldwide exome analysis · 2026 · DOI

  • Further studies are needed to investigate the relationship between genetic ancestry and GBC mutation profiles. Future research should aim to develop targeted therapies for GBC patients based on their genetic ancestry.

    Geographic and genetic diversity in gallbladder cancer mutation profiles: insights from a worldwide exome analysis · 2026 · DOI

  • Delayed presentation and advanced stage upon diagnosis. Limited treatment options for locally progressed and metastatic disease. The need for further validation of the clinical advantages of laparoscopic radical cholecystectomy for early gallbladder cancer.

    Influence of laparoscopic radical cholecystectomy for early gallbladder cancer on surgical performance, postoperative recuperation, and complication rates · 2026 · DOI

  • Limited awareness of IGBC among clinicians. Lack of routine histopathological examination of all cholecystectomy specimens. Limited resources for the management of IGBC in low-income settings.

    Incidental Gallbladder Carcinoma in Cholecystectomy Specimens: A Retrospective Study from Rajshahi Medical College Hospital · 2026 · DOI

  • Early detection of GBC is challenging due to non-specific symptoms. Treatment of GBC is challenging due to rapid local invasion and poor survival outcomes. Public health initiatives are needed to reduce the risk factors for GBC.

    Demographic, Clinical, Radiological, and Cytopathological Profiles of Patients With Gallbladder Carcinoma in Tripura: A Hospital-Based Cross-Sectional Study · 2026 · DOI

  • The treatment of MCC is challenging due to its aggressive clinical course and poor prognosis. The surgical approach for MCC is complex and requires careful consideration of tumor extent, lymph node metastasis, and patient condition. The study of MCC is limited by the lack of a comprehensive comparison of BDSR and PD.

    Bile duct segmental resection versus pancreaticoduodenectomy for middle-third extrahepatic cholangiocarcinoma: A propensity-matched, single-center retrospective analysis · 2026 · DOI

  • The aggressive nature of gallbladder cancer. The limited effectiveness of current treatment options. The need for personalized treatment approaches.

    Real-World Application of a Machine Learning-Based Early Recurrence Model for Guiding Adjuvant Chemotherapy Use in Patients with Gallbladder Cancer · 2026 · DOI

  • Molecular heterogeneity, chemoresistance, anatomical complexity, and high recurrence rates of Gallbladder cancer. Lack of understanding of the molecular pathogenesis of Gallbladder cancer.

    Transcriptomic landscape of Gallbladder cancer reveals altered pathways related to cell cycle and Aurora kinase · 2026 · DOI

  • Intrahepatic cholangiocarcinoma has aggressive biology and limited therapeutic options. Transarterial radioembolization requires precise dosimetric analysis to minimize variability. The study required a centralized dosimetric analysis to minimize variability.

    Dose–Response and survival analysis after transarterial radioembolization for intrahepatic cholangiocarcinoma: A multicenter multicompartment dosimetry study · 2026 · DOI

  • The rarity of cholangiocarcinoma makes it challenging to conduct large-scale studies. The lack of standardization in treatment regimens and prognostic factors hinders comparison across studies.

    Survival outcomes and prognostic factors in de novo advanced biliary tract cancer: insights from a Saudi multicenter cohort · 2026 · DOI

  • The tumor was initially unresectable due to extensive invasion and insufficient future liver remnant. The patient had a history of type 2 diabetes mellitus and hypertension.

    Case Report: Conversion therapy for initially unresectable intrahepatic cholangiocarcinoma · 2026 · DOI

  • Cholangiocarcinoma is a heterogeneous and aggressive malignancy. The incidence of cholangiocarcinoma is rising globally. Long-term survival remains sparse in patients with cholangiocarcinoma.

    Inflammation and RNA-Related Polymorphisms in Resected Cholangiocarcinoma: Prognostic Associations in Intrahepatic and Perihilar Tumors · 2026 · DOI

  • The lack of effective treatments for cholangiocarcinoma with IDH1R132 mutation. The limited evidence for the use of ivosidenib in this patient population.

    Systematic review of randomized clinical trials of patients with IDH1 R132-mutant cholangiocarcinoma treated with ivosidenib. · 2026 · DOI

  • The study faced challenges in terms of small sample size and limited generalizability. The study also faced challenges in terms of developing a robust and stable genomic classifier.

    Exploratory genomic stratification of benefit from first-line immunotherapy-based combination in advanced biliary tract cancer: a biomarker analysis of a randomized phase 2 trial · 2026 · DOI

  • The high heterogeneity of intrahepatic cholangiocarcinoma. The limited predictive performance of the AJCC staging system.

    Development of an HDL-C combined with AJCC staging system for predicting overall survival after curative resection of intrahepatic cholangiocarcinoma without metabolic comorbidities · 2026 · DOI

  • Intrahepatic cholangiocarcinoma is a rare and aggressive cancer with a poor prognosis. There are significant disparities in intrahepatic cholangiocarcinoma mortality across demographic and geographic groups. The study is limited by the use of death certificate data, which may be subject to errors or inconsistencies.

    Trends and disparities in intrahepatic cholangiocarcinoma mortality in the United States, 1999–2024: a CDC WONDER analysis · 2026 · DOI

  • The study is limited to analysis of mortality data and does not include incidence or survival data. The study uses death certificate data, which may be subject to errors or inconsistencies. Longitudinal race and ethnicity comparisons spanning 2020-2021 were interpreted cautiously due to differences in bridged-race and single-race classifications.

    Trends and disparities in intrahepatic cholangiocarcinoma mortality in the United States, 1999–2024: a CDC WONDER analysis · 2026 · DOI

  • Greater clinical awareness, a multidisciplinary approach, and further studies on targeted therapies are vital for improving outcomes in GB-NENs.

    Neuroendocrine neoplasms of the gallbladder: A case series and clinicopathological insights from a tertiary care hospital in Northeast India · 2026 · DOI

  • In cases of metastatic gallbladder adenocarcinoma, the potential benefit of primary tumor resection (PTR) in improving patient prognosis remains an unresolved issue that warrants further investigation.

    Prognostic implications and precision selection criteria of primary tumor resection in metastatic gallbladder adenocarcinoma · 2026 · DOI

  • Therapeutic targeting of organelle pathways including autophagy inhibitors, mitochondrial dynamics modulators, and ER stress inducers must be evaluated in preclinical cHCC-CCA models with systematic assessment of whether treatment efficacy correlates with the predominant lineage component (hepatocellular versus cholangiocarcinoma).

    From organelles to therapy: rethinking combined hepatocellular-cholangiocarcinoma · 2026 · DOI

  • Functional studies testing the specific roles of mitochondria, endoplasmic reticulum, and lysosomes in maintaining the biphenotypic state of cHCC-CCA are urgently needed, employing pharmacological inhibitors or genetic perturbations in patient-derived models to determine whether disrupting individual organelle systems selectively impairs hepatocellular versus cholangiocarcinoma lineage components.

    From organelles to therapy: rethinking combined hepatocellular-cholangiocarcinoma · 2026 · DOI

  • There is a lack of effective treatments for cholangiocarcinoma. Current evidence remains limited to early-phase trials. Larger studies are needed to establish clinical efficacy and optimal patient selection criteria.

    Harnessing cellular immunotherapy for cholangiocarcinoma: an integrated roadmap for overcoming resistance · 2026 · DOI

  • The incidence of metachronous double primary liver cancer is extremely low, with few relevant reports available. The diagnostic clues, potential pathogenesis, and therapeutic implications of metachronous double primary liver cancer are not well understood.

    Metachronous hepatocellular carcinoma after partial response of advanced intrahepatic cholangiocarcinoma treated with radiotherapy combined with apatinib and camrelizumab: a case report · 2026 · DOI

  • The study is retrospective in nature, which may introduce biases. The sample size of the external cohort is limited, with 203 patients. The study does not investigate the specific mechanisms by which NAT improves OS in high-risk iCCA patients.

    Neoadjuvant Therapy as a Selection Strategy for Curative Resection in High-Risk Intrahepatic Cholangiocarcinoma · 2026 · DOI

  • Further studies are needed to investigate the use of NAT in iCCA and to identify the most effective regimens. Research should focus on the specific mechanisms by which NAT improves OS in high-risk iCCA patients. The development of novel NAT regimens and the investigation of their efficacy in iCCA are necessary.

    Neoadjuvant Therapy as a Selection Strategy for Curative Resection in High-Risk Intrahepatic Cholangiocarcinoma · 2026 · DOI

Most-cited papers in Cholangiocarcinoma and Gallbladder Cancer Studies

Most recent work

Find a gap in your own Cholangiocarcinoma and Gallbladder Cancer Studies sub-topic

This page shows what the Cholangiocarcinoma and Gallbladder Cancer Studies literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Substance Abuse Treatment and Outcomes
1,213 open questions
Artificial Intelligence in Healthcare and Education
1,153 open questions
Physical Activity and Health
718 open questions
Dementia and Cognitive Impairment Research
565 open questions
Attention Deficit Hyperactivity Disorder
544 open questions
Smoking Behavior and Cessation
532 open questions
Innovations in Medical Education
480 open questions
HIV/AIDS Research and Interventions
472 open questions
93 open questions have been extracted from the limitations and future-work passages of 183 Cholangiocarcinoma and Gallbladder Cancer Studies papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.